Formosa Pharmaceuticals News

Formosa Pharmaceuticals and EirGenix establish a co-development alliance to develop TSY-0110 / EG12043 (ado-trastuzumab emtansine biosimilar) for HER2-positive breast cancer.

TAIPEI, Taiwan, March 24, 2022 – Formosa Pharmaceuticals, Inc. (6838.TWO) announce the approval of a resolution by the boards of directors of both Formosa Pharmaceuticals …

Read More →

Formosa Pharmaceuticals announce registration on Emerging Stock Board of the Taipei Stock Exchange (TPEx)

TAIPEI – October 5, 2021 – Formosa Pharmaceuticals (“Formosa”, stock code: 6838) announce its registration on the Emerging Stock Board of the Taipei Stock Exchange …

Read More →

Formosa Pharmaceuticals and China Grand Pharmaceutical and Healthcare Holdings Limited enter into licensing agreement for APP13007

(Corticosteroid for inflammation and pain after cataract surgery) TAIPEI – June 3, 2021 – Formosa Pharmaceuticals (“Formosa”, stock code:6838) and China Grand Pharma (“Grand”, HKG …

Read More →

Formosa Pharmaceuticals completes USD $21.1 million fundraising and increase in cash capital

April 16, 2021 Formosa Pharmaceuticals (FP), a subsidiary of Formosa Laboratories (TWSE 4746), has successfully completed a Series C financing round, increasing its cash capital …

Read More →

APP13007 completes Phase 2 clinical trial and EOP2 meeting.

Formosa Pharmaceuticals and AimMax Therapeutics report top-line results from a Phase 2 clinical trial of APP13007 for the treatment of inflammation and pain after cataract …

Read More →

Development Pipeline

Scroll to Top